Literature DB >> 17467966

Microbiologic follow-up study in adult bronchiectasis.

Paul T King1, Stephen R Holdsworth, Nicholas J Freezer, Elmer Villanueva, Peter W Holmes.   

Abstract

There is minimal published longitudinal data about pathogenic microorganisms in adults with bronchiectasis. Therefore a study was undertaken to assess the microbiologic profile over time in bronchiectasis. A prospective study of clinical and microbiologic outcomes was performed. Subjects were assessed by a respiratory physician and sputum sample were collected for analysis. Subjects were followed up and had repeat assessment performed. Eighty-nine subjects were followed up for a period of 5.7+/-3.6 years. On initial assessment the two most common pathogens isolated were Haemophilus influenzae (47%) and Pseudomonas aeruginosa (12%) whilst 21% had no pathogens isolated. On follow-up review results were similar (40% H. influenzae, 18% P. aeruginosa and 26% no pathogens). The prevalence of antibiotic resistance of isolates increased from 13% to 30%. Analysis of a series of H. influenzae isolates showed they were nearly all nontypeable and all were different subtypes. Subjects with no pathogens isolated from their sputum had the mildest disease, while subjects with P. aeruginosa had the most severe bronchiectasis. Many subjects with bronchiectasis are colonized with the same bacterium over an average follow-up of 5 years. Different pathogens are associated with different patterns of clinical disease.

Entities:  

Mesh:

Year:  2007        PMID: 17467966     DOI: 10.1016/j.rmed.2007.03.009

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  69 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 3.  Diagnosis and management of bronchiectasis.

Authors:  Maeve P Smith
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

Review 4.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

5.  Lobar distribution in non-cystic fibrosis bronchiectasis predicts bacteriologic pathogen treatment.

Authors:  S Izhakian; W G Wasser; L Fuks; B Vainshelboim; B D Fox; O Fruchter; M R Kramer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-12       Impact factor: 3.267

Review 6.  Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways.

Authors:  Sanjay H Chotirmall; Maria Teresa Martin-Gomez
Journal:  Mycopathologia       Date:  2017-05-17       Impact factor: 2.574

7.  Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation.

Authors:  Michael M Tunney; Gisli G Einarsson; Lan Wei; Maire Drain; Erich R Klem; Chris Cardwell; Madeleine Ennis; Richard C Boucher; Matthew C Wolfgang; J Stuart Elborn
Journal:  Am J Respir Crit Care Med       Date:  2013-05-15       Impact factor: 21.405

Review 8.  Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.

Authors:  Katrine Fjaellegaard; Melda Dönmez Sin; Andrea Browatzki; Charlotte Suppli Ulrik
Journal:  Chron Respir Dis       Date:  2016-08-09       Impact factor: 2.444

9.  Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Authors:  Heino Stass; Johannes Nagelschmitz; Stefan Willmann; Heinz Delesen; Abhishek Gupta; Sybille Baumann
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

Review 10.  The pathophysiology of bronchiectasis.

Authors:  Paul T King
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.